Stock analysts at StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biotechnology company's stock.
A number of other research analysts have also weighed in on the stock. LADENBURG THALM/SH SH lowered shares of Calithera Biosciences from a "buy" rating to a "neutral" rating in a report on Tuesday, November 15th. SVB Leerink lowered shares of Calithera Biosciences from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 15th.
Get Calithera Biosciences alerts:Calithera Biosciences Stock Performance
CALA stock opened at $0.38 on Monday. The firm has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.67. Calithera Biosciences has a fifty-two week low of $0.36 and a fifty-two week high of $14.87. The firm has a market cap of $1.85 million, a PE ratio of -0.01 and a beta of 1.31.
Calithera Biosciences (NASDAQ:CALA – Get Rating) last posted its earnings results on Monday, November 14th. The biotechnology company reported ($2.01) earnings per share for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.02). On average, equities analysts predict that Calithera Biosciences will post -8.62 EPS for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of Calithera Biosciences during the first quarter worth $404,000. Affinity Asset Advisors LLC bought a new stake in shares of Calithera Biosciences during the first quarter worth $404,000. Renaissance Technologies LLC lifted its position in shares of Calithera Biosciences by 36.5% during the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock worth $749,000 after purchasing an additional 496,100 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after purchasing an additional 72,865 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after purchasing an additional 26,800 shares during the last quarter. 33.73% of the stock is owned by hedge funds and other institutional investors.
Calithera Biosciences Company Profile
(Get Rating)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Featured Stories
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.